US claims matched 934 adults with type 2 diabetes using a glucose monitor on 80% or more days to 3,747 non-users starting a GLP-1 drug. At one year, 68.4% of monitor users were still on the drug as compared to 51.9% of non-users. The adjusted hazard ratio for stopping was 0.56, with matching on age, sex, ethnicity, therapy, comorbidity and insurance.
Why it is interesting: Monitor use tracks with persistence on GLP-1 drugs, where about half of non-users had stopped within a year.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.